SynthesisBMC cancer2020
Discrimination between clinical significant and insignificant prostate cancer with apparent diffusion coefficient - a systematic review and meta analysis.
Synthesis in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pretreatment Apparent Diffusion Coefficient Cannot Predict Histopathological Features and Response to Neoadjuvant Radiochemotherapy in Rectal Cancer: A Meta-Analysis.Digestive diseases (Basel, Switzerland) · 2022Pooled it
- Apparent diffusion coefficient cannot discriminate metastatic and non-metastatic lymph nodes in rectal cancer: a meta-analysis.International journal of colorectal disease · 2021Pooled it
- Combined ADC and TMagnetic resonance in medicine · 2026Article
- Quantitative Diffusion and T2 Mapping Using RF-Modulated Phase-Based Gradient Echo Imaging.Magnetic resonance in medicine · 2026Article
- Article
- IntegratedEJNMMI research · 2026Article
- Article
- Minimum ADC outperforms PSA and PSA density for predicting ISUP grade group in prostate cancer: a retrospective study of 192 patients undergoing radical prostatectomy.Frontiers in oncology · 2026Article
- Cross-Scanner Harmonization of AI/DL Accelerated Quantitative Bi-Parametric Prostate MRI.Sensors (Basel, Switzerland) · 2025Article
- Improved differentiation of prostate cancer using advanced diffusion models: a comparative study of mono-exponential, fractional-order-calculus, and multi-compartment models.Abdominal radiology (New York) · 2025Article
- Quantitative Prostate MRI, From theAJR. American journal of roentgenology · 2025Review
- Optimizing prostate cancer detection in transition zone: an analysis of apparent diffusion coefficient values in prostate magnetic resonance imaging evaluation with Prostate Imaging Reporting and Data System (PI-RADS) assessment.Translational andrology and urology · 2024Article
- Catalyzing Precision Medicine: Artificial Intelligence Advancements in Prostate Cancer Diagnosis and Management.Cancers · 2024Review
- Improved diagnostic accuracy of readout-segmented echo-planar imaging for peripheral zone clinically significant prostate cancer: a retrospective 3T MRI study.Scientific reports · 2024Article
- The role of magnetic resonance imaging in prostate cancer patients on active surveillance.The British journal of radiology · 2023Article
- Radiogenomics Analysis Linking Multiparametric MRI and Transcriptomics in Prostate Cancer.Cancers · 2023Article
- Clinical value of minimum apparent diffusion coefficient for prediction of clinically significant prostate cancer in the transition zone.International journal of clinical oncology · 2023Article
- Non-timely clinically applicable ADC ratio in prostate mpMRI: a comparison with fusion biopsy results.Abdominal radiology (New York) · 2022Article
- Emerging MR methods for improved diagnosis of prostate cancer by multiparametric MRI.Magma (New York, N.Y.) · 2022Review
- HyperpolarisedNature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate MRI has become a corner stone in diagnosis of prostate cancer (PC). Diffusion weighted imaging and the apparent diffusion coefficient (ADC) can be used to reflect tumor microstructure. The present analysis sought to compare ADC values of clinically insignificant with clinical significant PC based upon a large patient sample.
methodsMEDLINE library and SCOPUS databases were screened for the associations between ADC and Gleason score (GS) in PC up to May 2019. The primary endpoint of the systematic review was the ADC value of PC groups according to Gleason score. In total 26 studies were suitable for the analysis and included into the present study. The included studies comprised a total of 1633 lesions.
resultsClinically significant PCs (GS ≥ 7) were diagnosed in 1078 cases (66.0%) and insignificant PCs (GS 5 and 6) in 555 cases (34.0%). The pooled mean ADC value derived from monoexponenantially fitted ADC
conclusionsWe evaluated the published literature comparing clinical insignificant with clinically prostate cancer in regard of the Apparent diffusion coefficient values derived from magnetic resonance imaging. We identified that the clinically insignificant prostate cancer have lower ADC values than clinically significant, which may aid in tumor noninvasive tumor characterization in clinical routine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.